Monte Rosa Therapeutics (GLUE) Expected to Post Quarterly Earnings on Thursday

Monte Rosa Therapeutics (NASDAQ:GLUE) will likely be issuing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.3657) per share and revenue of $12.9140 million for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 14, 2026 at 9:30 AM ET.

Monte Rosa Therapeutics (NASDAQ:GLUE) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. The business had revenue of $4.21 million for the quarter, compared to analysts’ expectations of $10.95 million. On average, analysts expect Monte Rosa Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Monte Rosa Therapeutics Price Performance

Shares of GLUE stock opened at $16.08 on Wednesday. Monte Rosa Therapeutics has a 1-year low of $4.12 and a 1-year high of $25.77. The stock’s fifty day moving average price is $20.75 and its 200 day moving average price is $19.49. The company has a market cap of $1.36 billion, a price-to-earnings ratio of -10.86 and a beta of 1.59.

Insider Buying and Selling

In related news, insider Filip Janku sold 5,407 shares of Monte Rosa Therapeutics stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $24.50, for a total transaction of $132,471.50. Following the completion of the transaction, the insider directly owned 60,612 shares in the company, valued at approximately $1,484,994. This trade represents a 8.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Anthony M. Manning sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $23.11, for a total value of $231,100.00. Following the completion of the transaction, the director directly owned 10,000 shares of the company’s stock, valued at $231,100. The trade was a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 81,778 shares of company stock valued at $1,768,581 over the last quarter. 6.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Monte Rosa Therapeutics

Institutional investors have recently made changes to their positions in the company. Russell Investments Group Ltd. acquired a new position in shares of Monte Rosa Therapeutics in the 3rd quarter valued at $32,000. Lazard Asset Management LLC grew its position in Monte Rosa Therapeutics by 42.9% during the second quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock valued at $48,000 after buying an additional 3,262 shares during the period. Prudential Financial Inc. purchased a new position in Monte Rosa Therapeutics in the second quarter valued at $54,000. BNP Paribas Financial Markets increased its holdings in Monte Rosa Therapeutics by 88.3% in the third quarter. BNP Paribas Financial Markets now owns 9,733 shares of the company’s stock valued at $72,000 after buying an additional 4,565 shares in the last quarter. Finally, Sei Investments Co. acquired a new position in shares of Monte Rosa Therapeutics in the second quarter worth about $74,000. 79.96% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

GLUE has been the topic of several recent analyst reports. Weiss Ratings upgraded shares of Monte Rosa Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, July 28th. Jefferies Financial Group restated a “buy” rating on shares of Monte Rosa Therapeutics in a research note on Monday, July 27th. Wedbush dropped their price objective on shares of Monte Rosa Therapeutics from $37.00 to $27.00 and set an “outperform” rating on the stock in a report on Monday. JPMorgan Chase & Co. raised their target price on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Finally, Zacks Research downgraded Monte Rosa Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, July 6th. Seven analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $30.67.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.